Crucial Update for Long-Term Shareholders of CS Disco Inc. (NYSE: LAW), Five Below, Inc. (NASDAQ: FIVE), Humana Inc. (NYSE: HUM), and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Looking into Claims for You
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 24 2025
0mins
Should l Buy HUM?
Source: Globenewswire
CS Disco Inc. Securities Fraud Investigation: Grabar Law Office is investigating claims against CS Disco Inc. as a securities fraud class action complaint has survived a motion to dismiss, allowing shareholders who held shares before September 2, 2021, to seek corporate reforms and potential financial returns at no cost.
Five Below, Inc. Class Action Update: A similar investigation is underway for Five Below, Inc., where allegations of misleading financial information have also survived a motion to dismiss, enabling shareholders who held shares before December 1, 2022, to pursue corporate reforms and financial restitution.
Humana Inc. Shareholder Claims: Grabar Law Office is looking into potential breaches of fiduciary duties by Humana Inc. officers, with allegations of misleading statements regarding increased healthcare costs affecting shareholders who purchased shares before July 27, 2022, allowing them to seek reforms and financial returns.
Unicycive Therapeutics, Inc. Investigation: An investigation is being conducted for Unicycive Therapeutics, Inc. regarding false statements about FDA compliance and drug application prospects, with shareholders who held shares before March 29, 2024, eligible to seek corporate reforms and financial restitution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to rise
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 196.210
Low
231.00
Averages
290.39
High
344.00
Current: 196.210
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Remote Learning Enhances Respiratory Care Effectiveness
- Significant Educational Impact: A study by Humana Healthcare Research and University of Chicago Medicine in 2020 revealed that nearly 40% of the almost 2000 participants misused their inhalers at the program's start, but after the first phone education session, misuse dropped to below 7%, demonstrating the effectiveness of remote education.
- Importance of Ongoing Education: The research highlighted that continuous multi-session education is crucial for helping patients maintain correct inhaler use over time, with positive outcomes observed across all inhaler types and patient subgroups, underscoring the need for personalized guidance.
- Pharmacists' Key Role: Emily Thomas, a pharmacist at Humana, noted that the phone-based education program offers personalized guidance and support, helping patients improve their inhaler technique and better manage chronic obstructive pulmonary disease (COPD), which is essential for enhancing patients' quality of life.
- Future Research Directions: The study emphasizes the importance of continued research to develop tailored educational approaches for different patients to address the pervasive issue of inhaler misuse, ensuring that patients can effectively use respiratory inhalers to reduce COPD symptoms.
See More
Humana Declares Cash Dividend of $0.885 Per Share
- Dividend Declaration: Humana's Board of Directors has declared a cash dividend of $0.885 per share, scheduled for payment on July 31, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for June 26, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term investment among shareholders.
- Company Overview: Humana is a leading U.S. healthcare company focused on helping millions achieve their best health through insurance services and CenterWell healthcare services, enhancing accessibility and quality of care.
- Broad Service Reach: Humana serves a diverse clientele including Medicare and Medicaid beneficiaries, families, individuals, and military personnel, aiming to improve overall community quality of life and demonstrating the company's commitment to social responsibility in healthcare.
See More
Tuesday Health Partners with Humana to Expand Palliative Care Access
- Partnership Announcement: Tuesday Health's collaboration with Humana, set to launch on June 1, 2026, aims to provide value-based palliative care for Texans with serious illnesses, marking a significant step in the company's national expansion.
- Service Offerings: The program will offer eligible Humana members and their caregivers coordinated clinical guidance, proactive symptom management, and ongoing support designed to enhance quality of life and align care with individual goals.
- Team Support: Through this partnership, eligible Humana members will gain access to Tuesday Health's interdisciplinary care teams, including nurses, social workers, nurse practitioners, and physicians, who will assist in symptom management and complex medical decision-making.
- Market Demand: According to the Center to Advance Palliative Care, over 12 million Americans currently live with serious illnesses, a number expected to grow significantly with an aging population, highlighting the importance of value-based palliative care models in improving care experiences and supporting caregivers.
See More
Tuesday Health Partners with Humana to Expand Palliative Care Access
- Partnership Announcement: Tuesday Health has announced a partnership with Humana Inc. to launch a new program on June 1, 2026, aimed at providing value-based palliative care for Texans with serious illnesses, marking a significant step in the company's national expansion.
- Service Offerings: The program will provide eligible Humana members and their caregivers with coordinated clinical guidance, proactive symptom management, and ongoing support designed to enhance quality of life and ensure care aligns with individual goals.
- Team Collaboration: Through this partnership, eligible Humana members will gain access to Tuesday Health's interdisciplinary care teams, which include nurses, social workers, nurse practitioners, and physicians, who will work alongside existing clinicians to manage symptoms and guide complex medical decisions.
- Market Demand: According to the Center to Advance Palliative Care, over 12 million Americans currently live with serious illnesses, a number expected to grow significantly as the population ages, making value-based palliative care models essential for improving care experiences and supporting caregivers.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
Remote Learning Enhances Respiratory Care Effectiveness
- Significant Educational Impact: A study by Humana Healthcare Research and University of Chicago Medicine in 2020 revealed that nearly 40% of the almost 2000 participants misused their inhalers at the program's start, but after the first phone education session, misuse dropped to below 7%, demonstrating the effectiveness of remote education.
- Importance of Ongoing Education: The research highlighted that continuous multi-session education is crucial for helping patients maintain correct inhaler use over time, with positive outcomes observed across all inhaler types and patient subgroups, underscoring the need for personalized guidance.
- Pharmacists' Key Role: Emily Thomas, a pharmacist at Humana, noted that the phone-based education program offers personalized guidance and support, helping patients improve their inhaler technique and better manage chronic obstructive pulmonary disease (COPD), which is essential for enhancing patients' quality of life.
- Future Research Directions: The study emphasizes the importance of continued research to develop tailored educational approaches for different patients to address the pervasive issue of inhaler misuse, ensuring that patients can effectively use respiratory inhalers to reduce COPD symptoms.
See More
Humana Declares Cash Dividend of $0.885 Per Share
- Dividend Declaration: Humana's Board of Directors has declared a cash dividend of $0.885 per share, scheduled for payment on July 31, 2026, aimed at rewarding shareholders and enhancing investor confidence.
- Record Date for Shareholders: The record date for this dividend is set for June 26, 2026, ensuring that shareholders who own stock by this date will receive the dividend, thereby encouraging long-term investment among shareholders.
- Company Overview: Humana is a leading U.S. healthcare company focused on helping millions achieve their best health through insurance services and CenterWell healthcare services, enhancing accessibility and quality of care.
- Broad Service Reach: Humana serves a diverse clientele including Medicare and Medicaid beneficiaries, families, individuals, and military personnel, aiming to improve overall community quality of life and demonstrating the company's commitment to social responsibility in healthcare.
See More
Tuesday Health Partners with Humana to Expand Palliative Care Access
- Partnership Announcement: Tuesday Health's collaboration with Humana, set to launch on June 1, 2026, aims to provide value-based palliative care for Texans with serious illnesses, marking a significant step in the company's national expansion.
- Service Offerings: The program will offer eligible Humana members and their caregivers coordinated clinical guidance, proactive symptom management, and ongoing support designed to enhance quality of life and align care with individual goals.
- Team Support: Through this partnership, eligible Humana members will gain access to Tuesday Health's interdisciplinary care teams, including nurses, social workers, nurse practitioners, and physicians, who will assist in symptom management and complex medical decision-making.
- Market Demand: According to the Center to Advance Palliative Care, over 12 million Americans currently live with serious illnesses, a number expected to grow significantly with an aging population, highlighting the importance of value-based palliative care models in improving care experiences and supporting caregivers.
See More
Tuesday Health Partners with Humana to Expand Palliative Care Access
- Partnership Announcement: Tuesday Health has announced a partnership with Humana Inc. to launch a new program on June 1, 2026, aimed at providing value-based palliative care for Texans with serious illnesses, marking a significant step in the company's national expansion.
- Service Offerings: The program will provide eligible Humana members and their caregivers with coordinated clinical guidance, proactive symptom management, and ongoing support designed to enhance quality of life and ensure care aligns with individual goals.
- Team Collaboration: Through this partnership, eligible Humana members will gain access to Tuesday Health's interdisciplinary care teams, which include nurses, social workers, nurse practitioners, and physicians, who will work alongside existing clinicians to manage symptoms and guide complex medical decisions.
- Market Demand: According to the Center to Advance Palliative Care, over 12 million Americans currently live with serious illnesses, a number expected to grow significantly as the population ages, making value-based palliative care models essential for improving care experiences and supporting caregivers.
See More
Medicare Payment Increase Boosts CVS Stock Recovery
- Impact of Medicare Policy: The CMS's finalized Medicare payment increase of nearly 2.5% significantly improves the profitability outlook for CVS and other healthcare stocks, leading to a stock price rebound compared to the previously proposed 0.09% increase.
- Upgraded Earnings Expectations: Analysts project CVS's earnings per share to reach between $7 and $7.20 in 2026, with the increase in Medicare payments likely enhancing CVS's profitability and boosting market confidence.
- Stock Valuation Potential: Currently trading at around 11 times forward earnings, CVS could see its stock price rise to $90 or $100 if it narrows the valuation gap with competitors like UnitedHealth Group, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS not only provides steady income but also attracts long-term investors, further supporting the upward momentum of its stock price.
See More
CVS Health Stock Rebounds on Improved Medicare Payment Rates
- Medicare Rate Increase: The Centers for Medicare & Medicaid Services (CMS) finalized a 2.5% increase in Medicare payment rates, significantly better than the previously proposed 0.09%, which is expected to enhance CVS Health's profitability outlook and boost investor confidence.
- Earnings Forecast Adjustment: Analysts project CVS Health's earnings per share (EPS) to reach between $7 and $7.20 in 2026, with the increased Medicare payments potentially driving double-digit earnings growth in 2027, further propelling the stock price upward.
- Valuation Gap: CVS Health's current stock price trades at about 11 times forward earnings, while peers like UnitedHealth Group trade at 15 to 20 times; if CVS can partially close this valuation gap, its stock price could reasonably rise to $90 or $100, offering substantial investment returns.
- Stable Dividend Yield: With a forward dividend yield of 3.4%, CVS Health not only provides steady returns but, combined with the positive changes in Medicare policy, presents an attractive investment opportunity.
See More
